开放期刊系统

维立西呱在慢性心力衰竭患者中治疗效果的研究现状

唐 甜甜, 李 玉子

摘要

慢性心力衰竭(CHF)是各类心血管病终末阶段,以心肌舒缩异常、循环淤血、组织灌注不足为主要表现,发病率、再住院率与死亡率居高不下。目前心衰标准 “新四联” 方案可改善患者预后,但部分患者病情反复,仍存较高残余风险。维立西呱是新型 sGC 刺激剂,通过双重机制修复受损 NO-sGC-cGMP 信号通路,开辟了心衰治疗新靶点。本文总结近年国内外临床试验、指南及真实世界研究,从作用机制、药代、临床疗效、安全耐受性、用药要点、现存争议与发展前景等方面系统综述该药在慢性心衰中的研究现状,为临床用药及科研提供参考。

关键词

维立西呱;慢性心力衰竭;可溶性鸟苷酸环化酶;NT-proBNP

全文:

PDF


参考

[1]MASCOLO A, DI MAURO G, CAPPETTA D, et al. Current and future therapeutic perspective in chronic heart failure [J]. Pharmacol Res, 2022, 175: 106035.

[2]TSAO C W, ADAY A W, ALMARZOOQ Z I, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association [J]. Circulation, 2023, 147(8): e93-e621.

[3]BAJEC T, POGLAJEN G. Targeting the NO-sGC-cGMP Pathway: Mechanisms of Action of Vericiguat in Chronic Heart Failure [J]. Cells, 2025, 14(17).

[4]ARMSTRONG P W, PIESKE B, ANSTROM K J, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction [J]. N Engl J Med, 2020, 382(20): 1883-93.

[5]TRICARICO L, CORREALE M, BEVERE E M L, et al. The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice [J]. Rev Cardiovasc Med, 2025, 26(8): 39886.

[6]EZEKOWITZ J A, O'CONNOR C M, TROUGHTON R W, et al. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study [J]. JACC Heart Fail, 2020, 8(11): 931-9.

[7]REDDY Y N V, BUTLER J, ANSTROM K J, et al. Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial [J]. Eur J Heart Fail, 2025, 27(2): 209-18.

[8]BUTLER J, MCMULLAN C J, ANSTROM K J, et al. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial [J]. Lancet, 2025, 406(10510): 1341-50.

[9]GHEORGHIADE M, GREENE S J, BUTLER J, et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial [J]. Jama, 2015, 314(21): 2251-62.

[10]陈琳, 邬保川, 吴少军, et al. 真实世界中维立西呱联合“四联疗法”对射血分数降低型心力衰竭的疗效 [J]. 实用医学杂志, 2025, 41(09): 1379-86.

[11]高洁, 邹德俊, 梁晓燕, et al. 基于临床试验标准评价维立西呱在真实世界心力衰竭治疗中适用性的研究进展 [J]. 中国医院药学杂志, 2024, 44(06): 726-30+35.


(4 摘要 Views, 8 PDF Downloads)

Refbacks

  • 当前没有refback。